

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/049,953		
		Filing Date	February 19, 2002		
		First Named Inventor	Shannon et al.		
		Art Unit	To be assigned		
		Examiner Name	To be assigned		
Sheet	1	of	2	Attorney Docket Number	28594/38247

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
<i>WJ</i>	A1	5,591,632	01/07/1997	O'Donnell et al.
	A2	5,614,381	03/25/1997	Bromley et al.
	A3	5,736,146	04/07/1998	Cohen et al.
	A4	5,747,332	05/05/1998	Wallen et al.
	A5	5,776,465	07/07/1998	O'Donnell et al.
	A6	5,789,245	08/04/1998	Dubensky Jr. et al.
	A7	5,830,464	11/03/1998	Srivastava
	A8	5,837,251	11/17/1998	Srivastava

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		
<i>WJ</i>	B1	WO 95/24923	09/21/1995	Mount Sinai School of Medicine of the City University of New York
	B2	WO 96/37616	11/28/1996	The University of North Carolina at Chapel Hill et al.
	B3	WO 97/06685	02/27/1997	Sloan-Kettering Institute for Cancer Research
	B4	WO 97/06821	02/27/1997	Sloan-Kettering Institute for Cancer Research
	B5	WO 97/06828	02/27/1997	Sloan-Kettering Institute for Cancer Research
	B6	WO 97/10000	03/20/1997	Fordham University
	B7	WO 97/10001	03/20/1997	Fordham University
	B8	WO 97/10002	03/20/1997	Fordham University
	B9	WO 98/12208	03/26/1998	The University of New Mexico
	B10	WO 98/34641	08/13/1998	Fordham University
	B11	WO 98/34642	08/13/1998	Fordham University
	B12	WO 98/35705	08/20/1998	Whitehead Institute for Biomedical Research
	B13	WO 99/02670	01/21/1999	The Government of the United States as represented by The Secretary of the Department of Health and Human Services
	B14	WO 99/07860	02/18/1999	Stressgen Biotechnologies Corporation
	B15	WO 99/24049	05/20/1999	Protein Sciences Corporation
	B16	WO 00/10597	03/02/2000	Immunobiology Limited

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
<i>WJ</i>	C1	Barrios et al., "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Clamette Guerin priming," Eur. J. Immunol., 22(6):1365-72 (1992) (abstract only).		
<i>WJ</i>	C2	Blachere et al., "Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity," J. Exp. Med., 186(8):1315-22 (1997).		
<i>WJ</i>	C3	Bruschke et al., "An experimental multivalent bovine virus diarrhea virus E2 subunit vaccine and two experimental conventionally inactivated vaccines induce partial fetal protection in sheep," Vaccine, 17(15-16):1983-91 (1999) (abstract only).		

Examiner Signature	<i>[Signature]</i>	Date Considered	12/2/04
-----------------------	--------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹APPLICANT'S UNIQUE CITATION DESIGNATION NUMBER (OPTIONAL). ²APPLICANT IS TO PLACE A CHECK MARK HERE IF ENGLISH LANGUAGE TRANSLATION IS ATTACHED.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/049,953		
		Filing Date	February 19, 2002		
		First Named Inventor	Shannon et al.		
		Art Unit	To be assigned		
		Examiner Name	To be assigned		
Sheet	2	285 041	2	Attorney Docket Number	28594/38247

<input checked="" type="checkbox"/>	C4	Lussow et al., "Mycobacterial heat-shock proteins as carrier molecules," Eur. J. Immunol., 21(10):2297-302 (1991) (abstract only).	
<input type="checkbox"/>	C5	Perraut et al., "Successful primate immunization with peptides conjugated to purified protein derivative or mycobacterial heat shock proteins in the absence of adjuvants," Clin. Exp. Immunol., 93(3):382-6 (1993) (abstract only).	
<input type="checkbox"/>	C6	Przepiorka & Srivastava, "Heat shock protein-peptide complexes as immunotherapy for human cancer," Mol. Med. Today, 4(11):478-84 (1998) (abstract only).	
<input type="checkbox"/>	C7	Robert et al., "Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and hsp70," Eur. J. Immunol., 31:186-95 (2001).	
<input type="checkbox"/>	C8	Srivastava & Udono, "Heat shock protein-peptide complexes in cancer immunotherapy," Curr. Op Immunol., 6:728-32 (1994).	
<input type="checkbox"/>	C9	Srivastava et al., "Heat shock proteins come of age: primitive functions acquire new roles in an adoptive world," Immunity, 8:657-65 (1998).	
<input checked="" type="checkbox"/>	C10	Srivastava, "Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens," Methods, 12(2):165-71 (1997) (abstract only).	

Examiner Signature		Date Considered	12/2/01
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Form PTO-1449 (Modified)  INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28594/38247	Serial No. 10/049,953
	Applicant Shannon et al.		
	Filing Date February 19, 2002	Group TBA	

U.S. PATENT DOCUMENTS							
*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	

FOREIGN PATENT DOCUMENTS								
*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation		
						Yes	No	
W	B1	WO 98/23735	6/4/98	WO				
	B2	WO 99/07860	2/18/99	WO				
	B3	WO 99/29384	6/17/99	WO				
	B4	WO 99/42121	8/26/99	WO				
	B5	WO 99/42472	8/26/99	WO				
	B6	WO 00/20606	4/13/00	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
W	C1	International Search Report, International Application No. PCT/AU00/00988, International Filing Date 18 August 2000, Applicant Minister for Agriculture, Minister for Land and Water Conservation for and on Behalf of the State of New South Wales et al.
	C2	Rico et al., "Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice," <i>Infection and Immunity</i> , 66(1):347-352 (1998).
	C3	Schirmbeck et al., "Truncated of chimeric endogenous protein antigens gain immunogenicity for B cells by stress protein-facilitated expression," <i>European J. Immunol.</i> , 29(5): (1999).

EXAMINER 	DATE CONSIDERED 12/2/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	